ReviewCritical care clinics2020
Lubricin as a Therapeutic and Potential Biomarker in Sepsis.
Review in Critical care clinics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06266741 (The Predictive Value of Lubricin in Patients With Infective Endocarditis), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Predictive Value of Lubricin in Patients With Infective Endocarditis
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Mucin-Based Biomimetic Patches for Dynamic Heart Repair: Auxetic Structures and Translational Challenges.Cardiovascular engineering and technology · 2026Review
- Addition of PRG4 to Optimize the Anti-Adhesive Properties of Tissue Barrier SeprafilmAnnals of biomedical engineering · 2026Article
- Modulating the gut-bladder axis: fecal transplantation protects antibiotic-treated mice from E. coli cystitis via the Ahr/Prg4 pathway.Microbiome · 2025Article
- Enhanced lubricin secretion by human synovial mesenchymal stem cells compared to adipose mesenchymal stem cells.Stem cell research & therapy · 2025Article
- Stepwise targeting hyaluronic acid-based polymeric prodrug for acute kidney injury and prevents its progression to chronic kidney disease.Materials today. Bio · 2025Article
- Proteomic profiling of extracellular vesicles derived from human serum for the discovery of biomarkers in Avascular necrosis.Clinical proteomics · 2024Article
- Recombinant mucin biotechnology and engineering.Advanced drug delivery reviews · 2023Review
- Diagnostic and predictive values of pyroptosis-related genes in sepsis.Frontiers in immunology · 2023Article
- Organotypic heterogeneity in microvascular endothelial cell responses in sepsis-a molecular treasure trove and pharmacological Gordian knot.Frontiers in medicine · 2023Review
- Recombinant Human Proteoglycan-4 Mediates Interleukin-6 Response in Both Human and Mouse Endothelial Cells Induced Into a Sepsis Phenotype.Critical care explorations · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Proteoglycan 4 (or lubricin), a mucin-like glycoprotein, was originally classified as a lubricating substance within diarthrodial joints. More recently, lubricin has been found in other tissues and has been implicated in 2 inflammatory pathways within the cell, via the Toll-like receptors (TLRs) and CD44. Lubricin is an antagonist of TLR2 and TLR4, and appears to enter cells via the CD44 receptor. Because of lubricin's action on these receptors, downstream processes of inflammation are halted, thereby preventing release of cytokines (a hallmark of inflammation and sepsis) from the cell, indicating lubricin's role as a biomarker and possible therapeutic for sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.